share_log

维亚生物(01873)发布年度业绩 股东应占亏损1.16亿元 同比收窄78.03%

Viva Biotech (01873) announced annual results, losses attributable to shareholders of 116 million yuan narrowed by 78.03% year-on-year

Zhitong Finance ·  Mar 28 09:01

Viva Biotech (01873) announced its annual results for the year ended December 31, 2023, with group revenue of RMB 21...

According to the Zhitong Finance App, Viva Biotech (01873) announced results for the year ended December 31, 2023. The group's revenue was RMB 2,156 billion (same unit), a year-on-year decrease of 9.4%; loss attributable to shareholders was RMB 116 million, a year-on-year narrowing of 78.03%; and a loss of 0.06 yuan per share.

According to the announcement, the decline in revenue was mainly due to (1) the decline in global biomedicine investment in innovative drug research and development and the impact of the Group's strategic contraction on the EFS business; and (2) delays in orders from some CDMO customers.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment